| Target Price | $15.30 |
| Price | $7.85 |
| Potential |
94.90%
register free of charge
|
| Number of Estimates | 7 |
|
7 Analysts have issued a price target CorMedix Inc 2027 .
The average CorMedix Inc target price is $15.30.
This is
94.90%
register free of charge
$19.95
154.14%
register free of charge
$13.13
67.26%
register free of charge
|
|
| A rating was issued by 11 analysts: 10 Analysts recommend CorMedix Inc to buy, 1 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the CorMedix Inc stock has an average upside potential 2027 of
94.90%
register free of charge
|
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Revenue Million $ | 311.71 | 343.83 |
| 617.07% | 10.30% | |
| EBITDA Margin | 52.83% | 37.75% |
| 204.16% | 28.55% | |
| Net Margin | 52.31% | 11.82% |
| 226.83% | 77.40% |
7 Analysts have issued a sales forecast CorMedix Inc 2026 . The average CorMedix Inc sales estimate is
This results in the following potential growth metrics:
3 Analysts have issued an CorMedix Inc EBITDA forecast 2026. The average CorMedix Inc EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
7 CorMedix Inc Analysts have issued a net profit forecast 2026. The average CorMedix Inc net profit estimate is
This results in the following potential growth metrics and future Net Margins:
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Earnings Per Share $ | 2.03 | 0.52 |
| 776.67% | 74.38% | |
| P/E | 15.00 | |
| EV/Sales | 1.46 |
7 Analysts have issued a CorMedix Inc forecast for earnings per share. The average CorMedix Inc EPS is
This results in the following potential growth metrics and future valuations:
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Oppenheimer |
Locked
➜
Locked
|
Locked | Sep 23 2026 |
| RBC Capital |
Locked
➜
Locked
|
Locked | Aug 14 2026 |
| RBC Capital |
Locked
➜
Locked
|
Locked | Jul 07 2026 |
| Citizens |
Locked
➜
Locked
|
Locked | Apr 28 2026 |
| RBC Capital |
Locked
➜
Locked
|
Locked | Apr 28 2026 |
| Leerink Partners |
Locked
➜
Locked
|
Locked | Apr 28 2026 |
| D. Boral Capital |
Locked
➜
Locked
|
Locked | Apr 27 2026 |
| Analyst Rating | Date |
|---|---|
|
Locked
Oppenheimer:
Locked
➜
Locked
|
Sep 23 2026 |
|
Locked
RBC Capital:
Locked
➜
Locked
|
Aug 14 2026 |
|
Locked
RBC Capital:
Locked
➜
Locked
|
Jul 07 2026 |
|
Locked
Citizens:
Locked
➜
Locked
|
Apr 28 2026 |
|
Locked
RBC Capital:
Locked
➜
Locked
|
Apr 28 2026 |
|
Locked
Leerink Partners:
Locked
➜
Locked
|
Apr 28 2026 |
|
Locked
D. Boral Capital:
Locked
➜
Locked
|
Apr 27 2026 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


